Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to adjuvant radiochemotherapy in patients with primary cervical cancer - Results of a companion protocol of the randomized NOGGO-AGO phase III clinical trial

Anticancer Research

Volumn 34, Issue 1, 2014, Pages 385-391

  Braicu, Elena Ioana ^a   Gasimli, Khayal ^a   Richter, Rolf ^a   Nassir, Mani ^a   Kümmel, Sherko ^b   Blohmer, Jens Uwe ^c   Yalcinkaya, Isil ^a   Chekerov, Radoslav ^a   Ignat, Iulia ^a,d   Ionescu, Andra ^a,d   Mentze, Monika ^a   Fotopoulou, Christina ^a   Pop, Carmen ^a   Lichtenegger, Werner ^a   Sehouli, Jalid ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Hospital Essen Mitte   (Germany)

^c Sankt Gertrauden Hospital   (Germany)

^d IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^e TOC)

Author keywords

Cervical cancer; MMP2; MMP9; Radiochemotherapy response; TIMP2; VEGFA

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; GELATINASE A; GELATINASE B; PACLITAXEL; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN A; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; TIMP2 PROTEIN, HUMAN; TUMOR MARKER; VEGFA PROTEIN, HUMAN;

ADENOCARCINOMA; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; ADJUVANT CHEMORADIOTHERAPY; ARTICLE; BLOOD; CANCER GRADING; CONTROLLED CLINICAL TRIAL; FOLLOW UP; MIDDLE AGED; MORTALITY; PROGNOSIS; RADIOCHEMOTHERAPY RESPONSE; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TIMP2; TUMOR RECURRENCE; UTERINE CERVIX TUMOR; VEGFA;

CERVICAL CANCER; MMP2; MMP9; RADIOCHEMOTHERAPY RESPONSE; TIMP2; VEGFA;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84897026680     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. Jemal A et al: Global cancer statistics. CA Cancer J Clin 61(2): 69-90, 2011.
2. Forouzanfar MH et al: Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 378(9801): 1461-1484, 2011.
3. Parkin DM et al: Burden and trends of type-specific human papillomavirus infections and related diseases in the latin america and Caribbean region. Vaccine 26(Suppl 11): L1-15, 2008.
4. Mathew A and George PS: Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix - worldwide. Asian Pac J Cancer Prev 10(4): 645-650, 2009.
5. Vizcaino AP et al: International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer 86(3): 429-435, 2000.
6. Cuzick J et al: Chapter 10: New dimensions in cervical cancer screening. Vaccine 24(Suppl 3): S3/90-97, 2006.
7. Ronco G and Giorgi Rossi P: New paradigms in cervical cancer prevention: opportunities and risks. BMC Womens Health 8: 23, 2008.
8. Hazelbag S et al: Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer. Int J Cancer 112(6): 1020-1028, 2004.
9. Zhai Y et al: Expression of membrane type 1 matrix metalloproteinase is associated with cervical carcinoma progression and invasion. Cancer Res 65(15): 6543-6550, 2005.
10. Harry VN, Gilbert FJ and Parkin DE: Predicting the response of advanced cervical and ovarian tumors to therapy. Obstet Gynecol Surv 64(8): 548-560, 2009.
11. Shweiki D et al: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359(6398): 843-845, 1992.
12. Plate KH et al: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359(6398): 845-848, 1992.
13. Cheng WF et al: Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstet Gynecol 96(5 Pt 1): 721-726, 2000.
14. Ferrara N et al: The regulation of blood vessel growth by vascular endothelial growth factor. Ann NY Acad Sci 752: 246-256, 1995.
15. Willett CG et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10(2): 145-147, 2004.
16. Kabbinavar F et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21(1): 60-65, 2003.
17. Yang JC et al: A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5): 427-434, 2003.
18. Monk BJ et al: Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 27(7): 1069-1074, 2009.
19. Hurwitz H et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23): 2335-2342, 2004.
20. Pepper MS: Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 21(7): 1104-1117, 2001.
21. Libra M et al: Uterine cervical carcinoma: role of matrix metalloproteinases (review). Int J Oncol 34(4): 897-903, 2009.
22. Van Trappen PO et al: A model for co-expression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancer. Br J Cancer 87(5): 537-544, 2002.
23. Brooks R et al: Polymorphisms in MMP9 and SIPA1 are associated with increased risk of nodal metastases in early-stage cervical cancer. Gynecol Oncol 116(3): 539-543, 2010.
24. Bourboulia D and Stetler-Stevenson WG: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 20(3): 161-168, 2010.
25. Braicu EI et al: Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy. Cytokine 61(3): 755-758, 2013.
26. Lu H et al: The expression and clinical significance of matrix metalloproteinase 7 and tissue inhibitor of matrix metalloproteinases 2 in clear cell renal cell carcinoma. Exp Ther Med 5(3): 890-896, 2013.
27. Burger H et al: Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat 14(1): 22-34, 2011.
28. Shi TY et al: DNA polymerase zeta as a potential biomarker of chemoradiation resistance and poor prognosis for cervical cancer. Med Oncol 30(2): 500, 2013.
29. Sehouli J et al: A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study. Ann Oncol 23(9): 2259-2264, 2012.
30. Monk BJ, Tewari KS and Koh WJ: Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol 25(20): 2952-2965, 2007.
31. Van Trappen PO et al: Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol 201(4): 544-554, 2003.
32. Campo E et al: Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue. Hum Pathol 23(12): 1395-1401, 1992.
33. Zhu H et al: Profiling protein markers associated with the sensitivity to concurrent chemoradiotherapy in human cervical carcinoma. J Proteome Res 8(8): 3969-3976, 2009.
34. Choi CH et al: Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy. BMC Cancer 8: 295, 2008.
35. Gasparini G et al: Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer 69(3): 205-211, 1996.
36. Raspollini MR et al: Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer 14(5): 815-823, 2004.
37. Kuemmel S et al: Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer. Anticancer Res 29(2): 641-645, 2009.
38. Randall LM et al: Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecol Oncol 112(3): 583-589, 2009.
39. Loncaster JA et al: Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer 83(5): 620-625, 2000.
40. Hockel M et al: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56(19): 4509-4515, 1996.
41. Fyles AW et al: Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 48(2): 149-156, 1998.